VH mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia

作者: Alexander Kröber , Till Seiler , Axel Benner , Lars Bullinger , Elsbeth Brückle

DOI: 10.1182/BLOOD.V100.4.1410.H81602001410_1410_1416

关键词:

摘要: In chronic lymphocytic leukemia (CLL), biologic risk factors such as immunoglobulin variable heavy chain gene (V(H)) mutation status, CD38 expression level, and genomic aberrations have recently been identified, but the relative prognostic impact of individual parameters is unknown. current study, we analyzed V(H) status by polymerase reaction sequencing (n = 300), fluorescence in situ hybridization (+3q, 6q-, +8q, 11q-, +12q, 13q-, t(14q), 17p-) triple-color FACS (CD5, CD19, CD38) 157) a unicentric CLL cohort. The influence rate level was tested maximally selected log-rank statistics. A corrected P value (P(cor)) for cutoff allowing best separation 2 subgroups with different survival probabilities identified at 97% homology (95% confidence interval [CI], 96%-98% homology, P(cor) <.001) 7% CI, 20%-71% expression, =.02). univariate analyses, unmutated genes high levels predicted shorter times. overall incidence similar mutated subgroups. High-risk 17p- 11q- occurred almost exclusively subgroup, whereas favorable 13q- single abnormalities were overrepresented subgroup. multivariate analysis, V(H), 17p deletion, 11q age, WBC, LDH independent factors, indicating complementary role to predict outcome CLL.

参考文章(25)
Hartmut Dohner, Konstanze Fischer, Martin Bentz, Katrin Hansen, Axel Benner, Georges Cabot, Daniela Diehl, Richard Schlenk, Johannes Coy, Stephan Stilgenbauer, Martin Volkmann, Peter R Galle, Annemarie Poustka, Werner Hunstein, Peter Lichter, p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias Blood. ,vol. 85, pp. 1580- 1589 ,(1995) , 10.1182/BLOOD.V85.6.1580.BLOODJOURNAL8561580
KR Rai, A Sawitsky, EP Cronkite, AD Chanana, RN Levy, BS Pasternack, Clinical staging of chronic lymphocytic leukemia. Blood. ,vol. 46, pp. 219- 234 ,(1975) , 10.1182/BLOOD.V46.2.219.219
Stuart M. Lichtman, Philip Schulman, Vincent P. Vinciguerra, Kanti R. Rai, Manlio Ferrarini, Nicholas Chiorazzi, Rajendra N. Damle, Tarun Wasil, Franco Fais, Fabio Ghiotto, Angelo Valetto, Steven L. Allen, Aby Buchbinder, Daniel Budman, Klaus Dittmar, Jonathan Kolitz, Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. ,vol. 94, pp. 1840- 1847 ,(1999) , 10.1182/BLOOD.V94.6.1840
Terry J. Hamblin, Zadie Davis, Anne Gardiner, David G. Oscier, Freda K. Stevenson, Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. ,vol. 94, pp. 1848- 1854 ,(1999) , 10.1182/BLOOD.V94.6.1848
David R. Cox, Regression Models and Life-Tables Springer Series in Statistics. ,vol. 34, pp. 527- 541 ,(1992) , 10.1007/978-1-4612-4380-9_37
S el Rouby, A Thomas, D Costin, CR Rosenberg, M Potmesil, R Silber, EW Newcomb, p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression Blood. ,vol. 82, pp. 3452- 3459 ,(1993) , 10.1182/BLOOD.V82.11.3452.3452
J. L. Binet, A. Auquier, G. Dighiero, C. Chastang, H. Piguet, J. Goasguen, G. Vaugier, G. Potron, P. Colona, F. Oberling, M. Thomas, G. Tchernia, C. Jacquillat, P. Boivin, C. Lesty, M. T. Duault, M. Monconduit, S. Belabbes, F. Gremy, A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis Cancer. ,vol. 48, pp. 198- 206 ,(1981) , 10.1002/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO;2-V
Harry W. Schroeder, Guillermo Dighiero, The pathogenesis of chronic lymphocytic leukemia: analysis of the antibody repertoire Immunology Today. ,vol. 15, pp. 288- 294 ,(1994) , 10.1016/0167-5699(94)90009-4